Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...
NasdaqCM:CPRX Earnings and Revenue History November 13th 2024 Examining Cashflow Against Catalyst Pharmaceuticals' Earnings. One key financial ratio used to measure how well a com ...
4d
Catalyst Pharmaceuticals Inc (CPRX) reports a 25.3% increase in total revenue and updates its full-year guidance, while ...
Patrick J McEnany, Board Member at Catalyst Pharmaceuticals CPRX, reported an insider sell on November 13, according to a new SEC filing. Tracking the Thursday's morning session, Catalyst ...
Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...
Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...
Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback